?
Bhatia Sangeeta N.
Director
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1643921
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
5,081
Price per Share :
$419.92
Equivalence :
$2,133,613.52
Transaction History
-
M5,081 Shares After TransactionValue : $776,071.94$98,670.04Transaction Date : 08/30/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024.
-
S4,435 Shares After TransactionValue : $2,217,500.00Sold $323,000.00Transaction Date : 08/30/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024.
-
A4,902 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/01/24
-
Footnotes
-
-
Footnotes:#1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.#2 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023.
-
S4,435 Shares After TransactionValue : $1,787,083.25Sold $188,177.65Transaction Date : 05/02/24
-
Footnotes
-
-
Footnotes:#1 Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.#2 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023.
-
M5,727 Shares After TransactionValue : $874,741.98$197,340.08Transaction Date : 08/08/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2024.